REMARKS

The Specification and Claims have been amended to include sequence identification numbers which were omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the Specification and Claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 406462000210. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: November 7, 2001

By: Karen Babyak Dow

Karen Babyak Dow
Registration No. (29,684)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7960
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at page 8, line 4, has been amended as follows:

The endogenous hydrophobic sequence or the exogenous hydrophobic sequence is an amino acid sequence is preferably between about 5 and about 29 residues. Preferred short exogenous hydrophobic sequences are Phe-Leu-Leu-Ala-Val (SEQ ID NO:2) or Val-Ala-Leu-Leu-Phe (SEQ ID NO:3). The exogenous hydrophobic material may also be C8-C18 fatty acyl group, preferably lauroyl.

Paragraph beginning at page 26, line 3, has been amended as follows:

The results of several tests of the production and use of the present vaccine composition are detailed in TABLES 2-4. All vaccines were prepared as described below. Briefly, the peptides, with or wthout added cysteines, were synthesized by standard solid phase technology. While still on the resin, a lauroyl group was added to the amino aterminus as described below or the pentapeptide hydrophobic foot, Phe-Leu-Leu-Ala-Val (FLLAV) (SEQ ID NO:2), was added by simply continuing the synthesis. Except when noted otherwise, all vaccines were prepared by dissolving the peptides and/or the proteosomes in TEEN-1% detergent buffer and then exhaustively dialyzing away the detergent.

Paragraph beginning at page 31, line 9, has been amended as follows:

The synthetic DNA hydrophobic decapeptide anchor sequence (1 μg) identified below was then added and ligated to the SmaI/SalI cut pR32 (100ηg) in 30 μl ligase buffer with one unit of T4-DNA ligase at 4C for 16 hours. The hydrophobic decapeptide coding sequence was:

5' GGT GGT TAC TGC TTC GTT GCT CTG CTG TTC TGA G (SEQ ID NO:17)

3'CCA CCA ATG ACG AAG CAA CGA GAC GAC AAG ACT CAGCT (SEQ ID NO:18).

In the Claims:

Please amend claim 5 as follows:

5. (Amended) A vaccine composition according to claim 1 wherein the exogenous hydrophobic material is Phe Leu Leu Ala Val (SEQ ID NO:2) or Val Ala Leu Leu Phe (SEQ ID NO:3).